Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Investing.com -- Eli Lilly and Company (NYSE:LLY) fell 3% Monday, while Novo Nordisk (NYSE:NVO) rose 2% after Evercore ISI analyst Umer Raffat flagged a liver case in the FDA adverse event database that has "potential to create confusion" for Eli Lilly.
Ozempic oral pill will be produced entirely in the US and distributed through more than 70,000 pharmacies in the US.
Novo Nordisk (NYSE:NVO) is exploring semaglutide as a potential treatment for alcohol use disorder, expanding beyond its current uses in diabetes and obesity. The company has also begun Phase 1 trials for LX9851, an oral obesity and metabolic disorder drug developed with Lexicon Pharmaceuticals. These moves highlight ongoing clinical work in metabolic and related conditions, with implications for future treatment options. Novo Nordisk is currently trading at $43.88, with the share price up...
Is NVO a good stock to buy? We came across a bullish thesis on Novo Nordisk A/S on Unfair Advantage’s Substack by AK. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $38.52 as of April 23rd. NVO’s trailing and forward P/E were 10.65 and 11.38 respectively according […]
ON Semiconductor, Pfizer, Uber, McDonald’s, and many more will report earnings this week. Economic releases will include the April jobs report and purchasing managers index.
Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 9.5% in the afternoon session after it announced it would provide access to Novo Nordisk's oral semaglutide medication, known as the Ozempic pill, for eligible self-pay patients with type 2 diabetes.
Eli Lilly and Company (NYSE:LLY) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. Cramer noted that the company is “creating a lot of jobs,” as he said: Okay, then there’s one that’s totally away from manufacturing or industry or tech, and that’s Eli Lilly. It was up 10%. […]
Novo Nordisk (CPSE:NOVO B) is rolling out its oral Ozempic (semaglutide) tablet across the US as the only FDA approved oral GLP-1 for adults with type 2 diabetes. The company plans broad distribution through more than 70,000 US pharmacies. New access partnerships with WW International and GoodRx aim to support patients through digital health tools, discounts and self pay options. The launch includes a mix of insurance coverage pathways and cash pay programs targeting both insured and self...
The prescription data collected for Eli Lilly's new weight-loss pill, Foundayo, is flawed, analysts said Friday.
Oral version targets broader access as GLP-1 demand grows
Novo will sell 1.5 mg, 4 mg and 9 mg Ozempic pills as it rebrands Rybelsus in the US.
Oral version expands access to diabetes therapy
European equities traded in the US as American depositary receipts were trending marginally higher l
Beneath Eli Lilly's (LLY) headline numbers lies a structural business model shift that the broader market seems to currently undervalue, driven in part by a recent valuation penalty following Novo Nordisk's faster initial prescription ramp for its oral therapy. While early volume data favors the competitor’s established brand capture, the central equity debate remains focused on the friction between high demand and pricing pressure from pharmacy benefit managers. Critics highlight dropping reali
Novo Nordisk (NYSE:NVO) has drawn investor attention after recent share price moves, with the stock showing a monthly gain alongside weaker past 3 months and 1 year total returns, prompting closer examination of its fundamentals. See our latest analysis for Novo Nordisk. The recent rebound, including a 14.9% 1 month share price return and a 9.6% 7 day share price return, comes after weaker longer term total shareholder returns. As a result, the momentum currently appears more like a short...
ZTS eyes a Q1 beat as companion animal products and international growth offset U.S. weakness ahead of its May 7 earnings report.
AMGN beats Q1 estimates as 16 drugs post double-digit growth, offsetting biosimilar erosion and weaker legacy products while lifting 2026 outlook.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.